The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 30, 2021
Filed:
Mar. 17, 2015
Applicant:
Novartis Ag, Basel, CH;
Inventors:
Assignee:
NOVARTIS AG, Basel, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 49/00 (2006.01); A61K 9/00 (2006.01); A61K 31/277 (2006.01); A61K 31/472 (2006.01); A61K 31/4725 (2006.01); A61K 31/517 (2006.01); A61K 45/06 (2006.01); A61K 31/343 (2006.01); A61K 31/198 (2006.01); A61K 31/341 (2006.01); A61K 31/66 (2006.01); A61K 31/496 (2006.01); A61K 31/4025 (2006.01); A61K 31/14 (2006.01); A61K 31/381 (2006.01); A61K 31/502 (2006.01); A61F 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/08 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 49/00 (2013.01); A61F 9/0017 (2013.01); A61K 9/0014 (2013.01); A61K 9/0048 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 31/14 (2013.01); A61K 31/198 (2013.01); A61K 31/277 (2013.01); A61K 31/341 (2013.01); A61K 31/343 (2013.01); A61K 31/381 (2013.01); A61K 31/4025 (2013.01); A61K 31/472 (2013.01); A61K 31/4725 (2013.01); A61K 31/496 (2013.01); A61K 31/502 (2013.01); A61K 31/517 (2013.01); A61K 31/66 (2013.01); A61K 39/39533 (2013.01); A61K 45/06 (2013.01); C07K 16/2821 (2013.01); G01N 33/6893 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/92 (2013.01); G01N 2333/70503 (2013.01); G01N 2333/70525 (2013.01); G01N 2800/042 (2013.01); G01N 2800/164 (2013.01);
Abstract
The present invention provides compounds and methods for the treatment of diabetic retinopathy. In particular, LFA-1 antagonists are described herein to be used in the treatment of diabetic retinopathy. One aspect of the invention provides for diagnosis of diabetic retinopathy and administration of a LFA-1 antagonist, after the patient is diagnosed with diabetic retinopathy.